Biotech VC firm outlines plans for $100M fund
An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday. The VC firm has invested in at least five startups, according to public...
View ArticleFDA approves Zevra’s rare disease drug after resubmission
After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare genetic disease caused by the accumulation of certain fatty substances....
View ArticleYuhan ends cancer project with J&J as it signs API deal with Gilead on HIV...
Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing approval in the US for a similar drug. The South Korean pharma company...
View ArticleFTC to sue major PBMs over insulin rebates, claiming they inflated patient cost
The Federal Trade Commission said that it is suing the three major US pharmacy benefit managers over their role in the insulin market, claiming that the companies’ practice of using large rebates has...
View ArticleClik here to view.
European regulators reaffirm Apellis’ rejection, add eight positive...
Apellis has had its European ambitions dashed once again after regulators reaffirmed their decision to not recommend the company’s treatment for geographic atrophy due to age-associated blindness. The...
View ArticleFDA OKs the first-ever self-administered vaccine, for flu
Americans can now vaccinate themselves against the flu without the assistance of a healthcare worker. For the first time, the FDA approved a vaccine that people can administer themselves, clearing the...
View ArticleJ&J will defend its proposed 340B changes as US threatens penalties
The US’ Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the company’s involvement in the multibillion-dollar federal drug discount...
View ArticleWhy did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical...
This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her treating physician and get more information on the compounded weight loss drug...
View ArticleThe drug lobby's lawsuit against the IRA finds a sign of life after appeals...
The US Court of Appeals for the Fifth Circuit is reviving PhRMA’s legal attack on Medicare drug price negotiations. On Friday, the appeals court reversed a lower court’s ruling from earlier this year...
View ArticleClik here to view.
Sanofi's Sarclisa gets approved as a first-line option for some patients...
Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on Friday approved the anti-CD38 treatment as a first-line option for patients...
View ArticleClik here to view.
A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe
A small genetic testing startup backed by Peter Thiel’s Founders Fund and Reddit co-founder Alexis Ohanian’s 776 Fund is “considering the possibility of making a public offer to acquire 23andMe,...
View ArticleJ&J subsidiary files for third bankruptcy to settle talc claims
A Johnson & Johnson subsidiary filed for bankruptcy in its third attempt to settle a vast majority of cases alleging its talc products caused cancer. The $8 billion settlement plan would resolve...
View ArticleA small startup is challenging Epic's control over patient health records
A software startup has sued Epic on antitrust grounds, arguing that the electronic health records giant has orchestrated a scheme to destroy the startup’s business and maintain its monopoly over...
View ArticleClik here to view.
Biogen, UCB declare Phase 3 lupus win and prep a second trial, but details...
Biogen and UCB said Tuesday morning that data from a Phase 3 study for the lupus program dapirolizumab pegol were strong enough to convince it to launch a second pivotal trial to confirm the benefit...
View ArticleFlagship’s AI biotech Generate lands $65M upfront in Novartis deal, as first...
The AI-focused biotech Generate:Biomedicines announced another pharma partnership Tuesday, agreeing to work on several protein therapies with the Swiss drugmaking giant Novartis. Novartis will pay $50...
View ArticleConstructive Bio raises $58M for synbio work, and Nobel laureate joins board
A UK-based synthetic biology startup has brought in $58 million from private investors to fund its work engineering cell systems that can manufacture new and existing molecules. The company, called...
View ArticleClive Meanwell's new obesity biotech, Metsera, unveils early GLP-1 data with...
Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first clinical data just a few months after emerging with $290 million and a broad...
View ArticleHouse passes reauthorization of rare pediatric voucher program
The US House of Representatives on Monday afternoon unanimously passed a wide-ranging bill via voice vote that will reauthorize the rare pediatric priority review voucher program through 2029, among...
View ArticleClik here to view.
Updated: Gene therapy maker bluebird bio cuts costs again, lays off staff
Bluebird bio is cutting more jobs and expenses in the latest bid to manage its fragile finances as it supports the launch of its sickle cell gene therapy Lyfgenia. The company announced earlier Tuesday...
View ArticleHealth plan startup Centivo raises $75M
Centivo, a startup that sells health insurance to employers, raised $75 million in fresh funds months after it bought a virtual primary care startup to use in its offerings. The startup’s goal is to...
View Article